Ki-67 Expression as a Predictive Factor of Muscle Invasion in Bladder Cancer
DOI:
https://doi.org/10.3889/oamjms.2018.088Keywords:
Bladder cancer, Muscle invasive, Ki 67, Recurrence, ImmunohistochemistryAbstract
BACKGROUND: Bladder cancer is the 9th most frequent cancer worldwide. Ki-67 is immunohistochemistry marker that is predictive of cancer cell proliferation. The expression of Ki-67 is associated with poor prognosis in several types of malignancy, yet the value of Ki-67 as the prognostic factor in bladder cancer remains controversial. This study is aimed to investigate the association between Ki-67 expression with muscle-invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC).
METHODS: This was a case-control study with a retrospective design. The study was conducted at the Department of Pathology, University of Sumatera Utara, Indonesia. Samples were paraffin blocks from patients diagnosed with bladder cancer and agreed to be put in the study. The samples were stained with Immunohistochemistry Staining (IHC), and then we quantitatively counted the number of the Ki-67 stained nucleus on a microscope.
RESULTS: A total of 54 samples were obtained in this study. Samples consisted of 27 samples with NMIBC and 27 samples with MIBC. The cut-off point was 20%, we found 17 patients with MIBC and 14 patients with NMIBC presented with biomarker > 20%. Biomarker ≤ 20% was found in 10 patients with MIBC and 13 patients with NMIBC. On statistical analysis with Chi-Square test, no significant association found (p = 0.583) between KI-67 and muscle - invasiveness with OR of 1.579, 95% CI (0.533-4.678).
CONCLUSION: There is no association between expression of Ki-67 and muscle invasiveness in bladder cancer.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Burger M, Denzinger S, Hartmann A, Wieland W, Stoehr R, Obermann EC. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer. 2007; 96(11):1711-5. https://doi.org/10.1038/sj.bjc.6603784 PMid:17505513 PMCid:PMC2359908
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507(4792):315-22. PMid:24476821 PMCid:PMC3962515
Ranzi AD, da Silva JN, Graziottin TM, Annels N, Bica CG. Immunohistochemistry biomarkers in nonmuscle invasive bladder cancer. Appl Immunohistochem Mol Morphol. 2017; 25(3):178-83. https://doi.org/10.1097/PAI.0000000000000280 PMid:26574637
Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter, Wild PJ, et al. Immunhistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. J Cancer. 2017; 8(3):323-31. https://doi.org/10.7150/jca.17482 PMid:28261332 PMCid:PMC5332882
Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182(3):311-22. https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stohr R, et al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol. 2014; 65(1):218- 86. https://doi.org/10.1016/j.eururo.2012.05.033 PMid:22633802
Luo Y, Zhang X, Mo M, Tan Z, Huang L, Zhou H, et al. High Ki-67 immunohistochemical reactivity correlates with poor prognosis in bladder carcinoma: a comprehensive meta-analysis with 13,053 patients involved. Medicine (Baltimore). 2016; 95(15):e3337. https://doi.org/10.1097/MD.0000000000003337 PMid:27082587 PMCid:PMC4839831
Tian Y, Ma Z, Chen Z, Li M, Wu Z, Hong M, et al. Clinicopathological and prognostic value of Ki-67 expression in bladder cancer: a systematic review and meta-analysis. PLoS One. 2016; 11(7):e0158891. https://doi.org/10.1371/journal.pone.0158891 PMid:27410033 PMCid:PMC4943634
Otto W, Denzinger S, Fritsche HM, Burger M, Rößler W, Bertz S, et al. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of Ki-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients. Clinical Genitourinary Cancer. 2013; 11(4):537-44. https://doi.org/10.1016/j.clgc.2013.05.001 PMid:23850551
Jonat W, Arnold N. Is the Ki-67 labelling index ready for clinical use? Ann Oncol. 2011; 22(3):500–2. https://doi.org/10.1093/annonc/mdq732 PMid:21343384
Heslin MJ, Cordon-Cardo C, Lewis JJ, Woodruff JM, Brennan MF. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer. 1998; 83:490–7. https://doi.org/10.1002/(SICI)1097-0142(19980801)83:3<490::AID-CNCR18>3.0.CO;2-R
de Riese WT, Crabtree WN, Allhoff EP, Werner M, Liedke S, Lenis G, et al. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J Clin Oncol. 1993; 11(9):1804–8. https://doi.org/10.1200/JCO.1993.11.9.1804 PMid:7689094
Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, et al. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Pract. 1997; 193:767–75. https://doi.org/10.1016/S0344-0338(97)80055-6
Lei Y, Li Z, Qi L, Tong S, Li B, He W, et al. The prognostic role of Ki-67/MIB-1 in upper urinary-tract urothelial carcinomas: a systematic review and meta-analysis. J Endourol. 2015; 29(1):1302–8. https://doi.org/10.1089/end.2015.0420 PMid:26083161
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
